Robin has 25 years of U.S. and international experience in pharmaceutical and biotechnology sales, marketing, product development, and general management. Previously, Robin acted as the CEO of LaunchPoint BioMEMS, and Naryx Pharma. Additionally, Robin was the former VP and General Manager of the Oncology Business Unit at Amgen.
For nearly a decade, Scott has driven the realization of innovative solutions to major problems in health care. As CEO, he leverages his training in management and engineering science to develop and execute the corporate vision and strategy. To bring Aptitude's transformative value to market, Scott is responsible for customer development and strategic partnerships with industry leaders.
Prior to Aptitude, Scott has played an active role in multiple technology ventures including Cynvenio Biosytems, Ruubix, and Life Cube. He has pioneered technologies for personalized medicine and point of care diagnostics, authoring multiple patents, and peer-reviewed journal publications.
Trained in both life science research and management practice, Jackson brings to Aptitude both scientific and operational expertise. He has published 10+ peer-reviewed papers and co-invented the patent that serves as the foundation of Aptitude technology.
He has been an active member in the Sino-US startup community, having given invited talks in multiple forums and established Aptitude's connection to key collaborators. In Aptitude, Jackson oversees internal operation, customer interfacing, and R&D partnerships.
JP has focused his career on applying engineering principles to biological problems that promote scientific discovery and the development of new biomedical technologies and therapies. While pursuing his Ph.D. at the University of California, Santa Barbara, he has authored multiple peer-reviewed journal publications and is the lead inventor of Aptitude’s revolutionary aptamer discovery technology.
As CTO, JP shapes the company’s technical vision and R&D strategy, while overseeing internal R&D programs, establishing R&D collaborations, and leading the team of scientists.
Chris has 18 years of international experience in the pharmaceutical industry in roles covering strategic alliances and investments, new product development and sales and marketing with Pfizer and Eli Lilly. His responsibilities have included Head of Investments at The Pfizer Incubator, leading the structuring and negotiation of incubator company investments and technology licenses and providing operational oversight of the incubator portfolio. He has served in the positions of board director and observer, managed Pfizer’s portfolio of research collaboration-related capital investments, and structured and negotiated numerous equity investments in private and public biotech companies. Chris has extensive pharmaceutical product commercialization experience, including as commercial leader on Pfizer’s Chantix and Selzentry product development teams and in sales management for the launch of Lilly’s Zyprexa in the UK.
Jeremy has held several senior international commercial, sales and marketing positions within a variety of industry sectors including the Waters Corporation, Shimadzu, Whatman Healthcare, and Lab-21. In those roles, Jeremy managed global healthcare businesses in medical devices and diagnostics, including eight medical device manufacturing sites, and was responsibile for devising and implementing new product developments and overseeing technology and acquisitions. Jeremy has since launched Fulcrum Direct, which manages projects in commercializing life science and clinical diagnostics products.
Miguel is a dynamic Ph.D. biotechnology professional with over 8 years management experience in R&D, business development, and business strategy as founding CEO and CSO of Chimeros, Inc., a start-up biotechnology company. Miguel has established and managed partnerships with pharma and biotech companies, as well as universities and institutes.
Our technology originates from Professor H. Tom Soh's lab at the University of California, Santa Barbara, where he is the Ruth Garland Endowed chair, Co-Director at the Center for Stem Cell Biology & Engineering, and Associate Director of the California Nanosystems Institute. The technical leadership of the Soh Lab has been demonstrated in dozens of publications in top-tier journals and has been highlighted by Nature SciBX, Nature News and Views, Science Now, Nature Medicine. Prof. Soh has attracted over $20 M in funding from the NIH, DARPA, Keck Foundation, DOD, CIRM, and collaborations with leading pharmaceutical companies.